SEARCH

SEARCH BY CITATION

References

  • 1
    Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853860.
  • 2
    Hogg RS, O'Shaughnessy MV, Gataric N et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997; 349: 1294.
  • 3
    Menezes CN, Maskew M, Sanne I, Crowther NJ, Raal FJ. A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis 2011; 11: 244.
  • 4
    Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 20932099.
  • 5
    Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 14231430.
  • 6
    Galli M, Ridolfo AL, Adorni F et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002; 29: 2131.
  • 7
    Friis-Møller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 19932003.
  • 8
    Lindegaard B, Keller P, Bruunsgaard H, Gerstoft J, Pedersen BK. Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients. Clin Exp Immunol 2004; 135: 273279.
  • 9
    Palios J, Kadoglou NP, Lampropoulos S. The pathophysiology of HIV-HAART-related metabolic syndrome leading to cardiovascular disorders: the emerging role of adipokines. Exp Diabetes Res 2012; 2012: 103063.
  • 10
    Reingold J, Wanke C, Kotler D et al. Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr 2008; 48: 142148.
  • 11
    Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Frammingham Offspring study. Circulation 2004; 110: 380385.
  • 12
    Pai JK, Pischon T, Ma J et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351: 25992610.
  • 13
    Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009; 51: 268273.
  • 14
    Boulle A, Orrell C, Kaplan R et al. Substitution due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral treatment in a large South African cohort. Antivir Ther 2007; 12: 753760.
  • 15
    Mutimura E, Stewart A, Rheeder P, Crowther NJ. Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 46: 451455.
  • 16
    van Griensven J, Zachariah R, Rasschaert F, Mugabo J, Atte EF, Reid T. Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda. Trans R Soc Trop Med Hyg 2010; 104: 148153.
  • 17
    World Health Organization. Forecasting antiretroviral demand. 2010. Available at www.who.int/hiv/amds/forecasting/en/index4.html (accessed 20 April 2013).
  • 18
    National Department of Health. National Antiretroviral Treatment Guidelines, First Edition 2004: Available at www.doh.gov.za/docs/misc/2004/sec1.pdf (accessed 20 April 2013).
  • 19
    National Department of Health South Africa. 2010. Clinical guidelines for the management of HIV & AIDS in adults and adolescents: Available at www.health-e.org.za/documents/0ba405d9042e557a9fb1987adb68cb97.pdf (accessed 20 April 2013).
  • 20
    Schowalter L, Conradie F. Approaches to tenofovir and abacavir drug shortages in South Africa: a guide for clinicians. South Afr J HIV Med 2012; 13: 5657.
  • 21
    Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292: 191201.
  • 22
    Overton ET, Nurutdinova D, Freeman J, Seyfried W, Mondy KE. Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy. HIV Med 2009; 10: 343350.
  • 23
    Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40: 11941198.
  • 24
    Young B, Buchacz K, Baker RK et al. Renal function in tenofovir exposed and tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study. J Int Assoc Physicians AIDS Care (Chic Ill) 2007; 6: 178187.
  • 25
    Ryom L, Mocroft A, Kirk O et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis 2013; 207: 13591369.
  • 26
    Fux CA, Simcock M, Wolbers M et al. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther 2007; 12: 11651173.
  • 27
    Milinkovic A, Martinez E, López S et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther 2007; 12: 407415.
  • 28
    McComsey GA, LoRe III V, O'Riordan M et al. Effect of Reducing the Dose of Stavudine on Body Composition, Bone Density and Markers of Mitochondrial Toxicity in HIV infected Subjects- a Randomized, Controlled study. Clin Infect Dis 2008; 46: 12901296.
  • 29
    Hill A, Ruxrungtham K, Hanvanich M et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2007; 8: 679688.
  • 30
    Menezes CN, Duarte R, Dickens C et al. The early effects of stavudine compared to tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial. HIV Med 2013; 14: 217225.
  • 31
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 3141.
  • 32
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412419.
  • 33
    Nolan D, Hammond E, Martin A et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17: 13291338.
  • 34
    Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 31433421.
  • 35
    Rosen S, Long L, Fox M, Sanne I. Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. J Acquir Immune Defic Syndr 2008; 48: 334344.
  • 36
    Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17: 971979.
  • 37
    Magkos F, Mantzoros CS. Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment. Metabolism 2011; 60: 749753.
  • 38
    De Wit S, Sabin CA, Weber R et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008; 31: 12241229.
  • 39
    Savès M, Raffi F, Capeau J et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002; 34: 13961405.
  • 40
    Shlay JC, Visnegarwala F, Bartsch G et al. Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr 2005; 38: 147155.
  • 41
    Constans J, Pellegrin JL, Peuchant E et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994; 24: 416420.
  • 42
    Gallant JE, DeJesus E, Arribas JR et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251260.
  • 43
    Calmy A, Gayet-Ageron A, Montecucco F et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 2009; 23: 929939.
  • 44
    Dzwonek AB, Novelli V, Schwenk A. Serum leptin concentrations and fat distribution in HIV-1 infected children on highly active antiretroviral therapy. HIV Med 2007; 8: 433438.
  • 45
    Bezante GP, Briatore L, Rollando D et al. Hypoadiponectinemia in lipodystrophic HIV individuals: a metabolic marker of subclinical cardiac damage. Nutr Metab Cardiovasc Dis 2009; 19: 277282.